Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE

SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed journal article featuring analytical validation results demonstrating the high sensitivity of the Company's Target Selector™ testing for EGFR, BRAF, and KRAS mutations in plasma circulating tumor DNA (ctDNA). The article was published in the journal, PLOS ONE, Volume 14, October 2019, and will also be included as part of a special collection of topical articles, entitled Targeted Anticancer Therapies And Precision Medicine In Cancer. 

Key points from the article include:

• Target Selector™ testing for EGFR, BRAF, and KRAS mutations has been validated to an ultra-sensitive single copy level, with a limit of detection (LOD) of 0.02% or better
• Biocept's biomarker tests provide coverage for the most common actionable mutations associated with clinical guidelines for targeted cancer therapy
• Target Selector™ tests performed in Biocept's laboratory provide a commercial turnaround time of 3-4 days, and offer a cost-effective strategy to guide treatment decisions and monitor therapeutic response

"Biocept's patented Switch-Blocker™ technology uniquely amplifies mutations of interest from the blood of patients with cancer, while blocking wild type DNA. This enables very high sensitivity and detection down to a single gene copy," said Jason Poole, Vice President of Research and Development at Biocept and the study's lead author. "We are very pleased to have this analytical validation published in PLOS ONE, and believe the results demonstrate the high sensitivity and performance of our novel liquid biopsy assays, which are designed to provide oncologists with the information they need to select the right targeted therapy for their patients."

Michael Nall, Biocept's President and CEO added, "This peer-reviewed publication provides further data supporting the clinical utility of our Target Selector™ technologies focused on actionable biomarkers. This testing is available as a laboratory service in our CLIA-certified and CAP-accredited facility and in Research Use Only (RUO) kits that can be performed in a customer's laboratory. Target Selector™ liquid biopsy continues to emerge as an important tool to cost-effectively qualify patients for therapy and, importantly, monitor therapeutic response and disease progression for physicians and their patients with cancer. Biocept provides physicians and hospital systems with the choice of liquid biopsy laboratory services, kits and blood collection tubes, as customers assess ways to adopt liquid biopsy in their standard of care protocols."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of patients diagnosed with cancer and the potential clinical utility of our proprietary technology platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at http://www.sec.gov/.

Contact:
LHA Investor Relations
Jody Cain
[email protected]
310-691-7100

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-ctdna-platform-demonstrates-single-copy-detection-for-egfr-braf-and-kras-mutations-study-results-published-in-peer-reviewed-journal-plos-one-300932753.html

SOURCE Biocept, Inc.